Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat...
August 03, 2023 18:00 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
August 03, 2023 17:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Announces Leadership Transition

FOSTER CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
July 18, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

FOSTER CITY, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
July 05, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
June 26, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events

TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model Company to participate in upcoming Piper Sandler...
June 06, 2023 16:30 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
June 02, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
May 25, 2023 17:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose...
May 24, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...